VEEV Stock Recent News

The Saudi Arabia Pharmaceutical Quality Management Software Market is projected to grow from USD 14.48 Million in 2024 to USD 26.92 Million by 2030, with a CAGR of 10.85%. This growth is driven by the expansion of the pharmaceutical industry and the increasing adoption of digital solutions like AI and cloud computing to enhance quality control. Compliance with strict regulatory standards and the push towards automation are also key factors in the market's development. Vision 2030 initiatives further boost the demand for innovative PQMS solutions to support the burgeoning pharmaceutical sector. The Saudi Arabia Pharmaceutical Quality Management Software Market is projected to grow from USD 14.48 Million in 2024 to USD 26.92 Million by 2030, with a CAGR of 10.85%. This growth is driven by the expansion of the pharmaceutical industry and the increasing adoption of digital solutions like AI and cloud computing to enhance quality control. Compliance with strict regulatory standards and the

xAI Holdings led performance with rapid AI innovation, Grok 3 launch, and the acquisition of X, positioning it as an AI industry leader. MercadoLibre delivered strong revenue and margin growth, reinforcing confidence in its leadership in Latin American e-commerce and fintech. Nvidia, despite a stock correction, remains a high-conviction holding due to its dominant AI platform and robust datacenter growth.

In the most recent trading session, Veeva Systems (VEEV) closed at $240.30, indicating a -0.37% shift from the previous trading day.

In the closing of the recent trading day, Veeva Systems (VEEV) stood at $239.53, denoting a +0.51% change from the preceding trading day.

PLEASANTON, Calif. , May 7, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its first quarter, which ended April 30, 2025, after market close on May 28, 2025.

AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, and more share strategies for more connected customer experiences across sales, marketing, and medical PLEASANTON, Calif. , May 6, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced its keynote speakers for the 2025 Veeva Commercial Summit, May 13-14 in Boston.

I believe Veeva's robust product roadmap, including the introduction of Veeva AI, should deepen adoption and drive productivity across its Development and Commercial Cloud segments. Despite a projected revenue growth slowdown in FY26, Veeva's management remains confident in achieving its $6B revenue target by 2030. VEEV's strong financial discipline is evident, with non-GAAP operating margins expected to expand to 43% in FY26 despite a projected revenue slowdown.

DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued at US$35.69 billion in 2024, is forecasted to grow at a robust CAGR of 11.4%, reaching US$40.03 billion in 2025 and an impressive US$68.81 billion by 2030. The standardization of diverse datasets from sources such as clinical trials, electronic health records (EHRs), genomics, and real-world evidence is essential for the efficient exchange of information across various platforms and geographical regions. This standardization enhances multi-site clinical trials and cross-border research collaborations. Additionally, emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights. These technologies help simplify reports and create interactive dashboards. Furthermore, the increasing adoption of analytics in pre-clinical trials, drug discovery, and clinical trials, particul

Veeva Systems (VEEV) closed the most recent trading day at $232.07, moving -0.69% from the previous trading session.

Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.